Platinum-Resistant Ovarian Cancer ARTISTRY-7
Dosing: Nemvaleukin (IV) Monotherapy and Combination with Pembrolizumab (Potentially
Registrational)
Anticipated Program Milestone:
Interim readout expected in Q1 2025, with final OS projected in 1H 2026 (subject to event accrual)
>> Learn more about Nemvaleukin Alfa
>> Visit the ARTISTRY-7 study website